Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology.
暂无分享,去创建一个
Thomas J. Smith | Michael A. Friedman | Harrison Ball | Janet Woodcock | Robert Justice | Susan K. Parsons | Rodger J. Winn | Patricia A. Ganz | Mark Levine | R. Gelber | J. Woodcock | R. Winn | P. Ganz | J. Weeks | C. Bennett | M. Levine | L. Ford | P. Legant | C. Cobau | R. Justice | S. Parsons | A. Cohen | H. Grier | Richard D. Gelber | J. Fetting | P. N. Anderson | H. Ball | J. Benear | K. Benjamin | S. Braun | H. Brereton | J. Burrows | M. Friedman | G. Hanks | Raich Pc | S. Schafer | Collier Smyth | A. Oosterom | J. Wade | Susan Braun | Charles L. Bennett | John H. Fetting | Paul N. Anderson | John Benear | Katy Benjamin | Harmar Brereton | John Burrows | Charles D. Cobau | Alfred M. Cohen | Leslie C. Ford | Holcombe Grier | Gerald Hanks | Patricia Legant | Raich Pc | Sandra Schafer | Collier Smyth | A. T. Van Oosterom | James L. Wade | Jane C. Weeks
[1] W. Gregory,et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. , 1990, BMJ.
[2] J. Hanley,et al. The effect of measuring error on the results of therapeutic trials in advanced cancer , 1976, Cancer.
[3] S. Kaasa,et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis , 1993, The Lancet.
[4] G. Guyatt,et al. Measuring disease-specific quality of life in clinical trials. , 1986, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[5] E. Messing,et al. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Skeel. Quality of life dimensions that are most important to cancer patients. , 1993, Oncology.
[7] A. Detsky,et al. A clinician's guide to cost-effectiveness analysis. , 1990, Annals of internal medicine.
[8] R. Souhami,et al. Quality of life during chemotherapy for small cell lung cancer: assessment and use of a daily diary card in a randomized trial. , 1990, European journal of cancer.
[9] F. Cavalli,et al. Quality-of-Life-Adjusted Evaluation of Adjuvant Therapies for Operable Breast Cancer , 1991 .
[10] A. Oxman,et al. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Peto,et al. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. , 1989, The New England journal of medicine.
[12] R. Wittes,et al. Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[14] B. Hillner,et al. Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis. , 1993, Journal of the National Cancer Institute.
[15] E. M. Jones,et al. A comparison of subjective responses in a trial comparing endocrine with cytotoxic treatment in advanced carcinoma of the breast. , 1980, European journal of cancer.
[16] W. Gregory,et al. Who should measure quality of life, the doctor or the patient? , 1988, British Journal of Cancer.
[17] P Glasziou,et al. Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] D. Tulsky,et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] G. Morrow. The Assessment of Nausea and Vomiting , 1984 .
[20] N. Boyd,et al. Ratings of the importance of quality of life variables: therapeutic implications for patients with metastatic breast cancer. , 1990, Journal of clinical epidemiology.
[21] P. Ganz,et al. Assessing the quality of life--a study in newly-diagnosed breast cancer patients. , 1990, Journal of clinical epidemiology.
[22] I. Tannock,et al. Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] R. Gelman,et al. Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. , 1988, Cancer research.
[24] M. Tattersall,et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. , 1987, The New England journal of medicine.
[25] G. Guyatt,et al. Quality of life in stage II breast cancer: an instrument for clinical trials. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] R. Sanson-Fisher,et al. Measuring quality of life in cancer patients. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] C. Moinpour,et al. Quality of life end points in cancer clinical trials: review and recommendations. , 1989, Journal of the National Cancer Institute.
[28] W H Rogers,et al. Patients' ratings of outpatient visits in different practice settings. Results from the Medical Outcomes Study. , 1993, JAMA.
[29] T M Gill,et al. A critical appraisal of the quality of quality-of-life measurements. , 1994, JAMA.
[30] R. Bast,et al. The CA 125 tumour-associated antigen: a review of the literature. , 1989, Human reproduction.
[31] Andriole Gl,et al. Serum PSA after antiandrogen therapy. , 1993 .
[32] G. Guyatt,et al. Measuring change over time: assessing the usefulness of evaluative instruments. , 1987, Journal of chronic diseases.
[33] Earlybreastcancertrialistscol,et al. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.
[34] R. McCorkle. The measurement of symptom distress. , 1987, Seminars in oncology nursing.
[35] Y. Komada,et al. Improved therapy for children with acute lymphoblastic leukemia. , 1996, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[36] D. Cook,et al. Health status, quality of life, and the individual. , 1994, JAMA.